Literature DB >> 23598959

Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist.

Alina Nicolae1, Stefania Pittaluga, Girish Venkataraman, Anahi Vijnovich-Baron, Liqiang Xi, Mark Raffeld, Elaine S Jaffe.   

Abstract

Peripheral T-cell lymphomas (PTCLs) are functionally and morphologically complex. Epstein-Barr virus (EBV)-positive B cells have been reported in angioimmunoblastic T-cell lymphoma (AITL) and other PTCLs and may mimic Hodgkin/Reed-Sternberg (HRS) cells, but EBV-negative HRS-like B cells have not been described. We wished to assess the nature of the PTCL associated with HRS-like cells and to determine whether EBV-negative HRS-like cells may be seen. We identified 57 PTCL cases reported as containing HRS-like cells. These included 32 AITL, 19 PTCL, not otherwise specified (NOS), 3 PTCL-NOS, follicular variant, 1 PTCL-NOS, T-zone variant, and 2 adult T-cell leukemia/lymphoma cases. All patients were adults with a median age of 63 and presented with lymphadenopathy. The male:female ratio was 31:26 (1.2:1). Clonal TRG rearrangement was detected in 46/53 cases. Six of 38 cases had a concomitant clonal immunoglobulin gene rearrangement. In 52/57 cases the HRS cells were positive for EBV. Five cases, 3 classified as AITL and 2 as PTCL-NOS, follicular variant, contained HRS-like cells negative for EBV. All PTCLs with EBV-negative HRS cells had a T follicular helper cell immunophenotype. The neoplastic T cells expressed CD3, CD4, and PD-1 and formed rosettes around the HRS-like cells. The HRS-like cells were positive for CD20 (variable intensity), PAX5, CD30, and CD15 (4/5). We conclude that both EBV-positive and EBV-negative HRS-like B cells may occur in the background of PTCL; caution is needed to avoid misdiagnosis as classical Hodgkin lymphoma. The close interaction between the HRS-like cells and the rosetting PD-1-positive T cells suggests a possible pathogenetic role in this phenomenon and provides new insights into the abnormal B-cell proliferations that occur in the context of TFH malignancies.

Entities:  

Mesh:

Year:  2013        PMID: 23598959      PMCID: PMC3654051          DOI: 10.1097/PAS.0b013e3182785610

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  38 in total

1.  Angioimmunoblastic T-cell lymphoma partially obscured by an Epstein-Barr virus-negative clonal plasma cell proliferation.

Authors:  Alison R Huppmann; Michele R Roullet; Mark Raffeld; Elaine S Jaffe
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

Review 2.  Composite angioimmunoblastic T-cell lymphoma and diffuse large B-cell lymphoma: a case report and review of the literature.

Authors:  Yin Xu; Robert W McKenna; Mai P Hoang; Robert H Collins; Steven H Kroft
Journal:  Am J Clin Pathol       Date:  2002-12       Impact factor: 2.493

3.  Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified.

Authors:  Andreas Zettl; Seung-Sok Lee; Thomas Rüdiger; Petr Starostik; Mirella Marino; Thomas Kirchner; Michaela Ott; Hans Konrad Müller-Hermelink; German Ott
Journal:  Am J Clin Pathol       Date:  2002-03       Impact factor: 2.493

4.  Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10.

Authors:  Ayoma Attygalle; Rajai Al-Jehani; Tim C Diss; Phillipa Munson; Hongxiang Liu; Ming-Qing Du; Peter G Isaacson; Ahmet Dogan
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

5.  The distribution of gene segments in T-cell receptor gamma gene rearrangements demonstrates the need for multiple primer sets.

Authors:  Lyle C Lawnicki; Ronald J Rubocki; Wing C Chan; Deborah M Lytle; Timothy C Greiner
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

Review 6.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Curr Opin Immunol       Date:  2012-01-09       Impact factor: 7.486

7.  European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.

Authors:  I Anagnostopoulos; M L Hansmann; K Franssila; M Harris; N L Harris; E S Jaffe; J Han; J M van Krieken; S Poppema; T Marafioti; J Franklin; M Sextro; V Diehl; H Stein
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

8.  Peripheral T-cell lymphomas expressing CD30 and CD15.

Authors:  Todd S Barry; Elaine S Jaffe; Lynn Sorbara; Mark Raffeld; Stefania Pittaluga
Journal:  Am J Surg Pathol       Date:  2003-12       Impact factor: 6.394

9.  Imbalances of chemokines, chemokine receptors and cytokines in Hodgkin lymphoma: classical Hodgkin lymphoma vs. Hodgkin-like ATLL.

Authors:  Koichi Ohshima; Kennosuke Karube; Makoto Hamasaki; Hiroaki Suefuji; Takeshi Tutiya; Takahiro Yamaguchi; Junji Suzumiya; Masahiro Kikuchi
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

10.  Survival and clonal expansion of mutating "forbidden" (immunoglobulin receptor-deficient) epstein-barr virus-infected b cells in angioimmunoblastic t cell lymphoma.

Authors:  A Bräuninger; T Spieker; K Willenbrock; P Gaulard; H H Wacker; K Rajewsky; M L Hansmann; R Küppers
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

View more
  25 in total

Review 1.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

Review 2.  Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma.

Authors:  Manabu Fujisawa; Shigeru Chiba; Mamiko Sakata-Yanagimoto
Journal:  J Clin Exp Hematop       Date:  2017

Review 3.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 4.  Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Manli Jiang; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2017-01-29       Impact factor: 2.929

5.  MUM-1 expression differentiates AITL with HRS-like cells from cHL.

Authors:  Wenyong Huang; Jianlan Xie; Xiao Xu; Xue Gao; Ping Xie; Xiaoge Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 6.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

7.  IL-21-driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-cell lymphoma.

Authors:  Shweta Jain; Jing Chen; Alina Nicolae; Hongsheng Wang; Dong-Mi Shin; Elisabeth B Adkins; Thomas J Sproule; Caroline M Leeth; Tomomi Sakai; Alexander L Kovalchuk; Mark Raffeld; Jerrold M Ward; Jerold E Rehg; Thomas A Waldmann; Elaine S Jaffe; Derry C Roopenian; Herbert C Morse
Journal:  Am J Pathol       Date:  2015-09-09       Impact factor: 4.307

Review 8.  Pathobiology of T-cell and NK-cell lymphomas.

Authors:  Ewa B Bajor-Dattilo; Stefania Pittaluga; Elaine S Jaffe
Journal:  Best Pract Res Clin Haematol       Date:  2013-05-23       Impact factor: 3.020

Review 9.  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Authors:  A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 10.  Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.

Authors:  Ryan C Lynch; Dita Gratzinger; Ranjana H Advani
Journal:  Curr Treat Options Oncol       Date:  2017-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.